Antisenescence vaccine increases mouse lifespan by 12%
A late-life antisenescence vaccine increases mouse median lifespan by about 12% in female mice, according to research covered by Lifespan.io. The three-element senolytic nanovaccine lowered senescence markers and improved metabolic measures when given in old age, though small group sizes and short-lived controls mean the finding still needs stronger confirmation.
The work, summarized by the Lifespan Research Institute, describes a vaccine designed to help the aging immune system clear senescent “zombie” cells. For readers tracking longevity and biohacking research, a late-life gain of this size is notable—if it holds up under stricter testing.
Key Takeaways
- A three-element CK5-based senolytic nanovaccine raised median lifespan about 12% when given to normally fed female mice at 75 weeks of age.
- The vaccine targets Gpnmb on senescent cells, uses CpG DNA as an adjuvant, and packages ingredients in a CK5 nanoparticle scaffold.
- Treated mice showed lower senescence markers in fat tissue and better glucose regulation without meaningful changes in body weight or food intake.
- Experiments used only 10 mice per group, and control animals were relatively short-lived for C57BL/6 mice, so replication is essential.
What did the antisenescence vaccine do in mice?
Researchers published in Advanced Science reported a bi-adjuvant senolytic nanovaccine aimed at dendritic cells. Those immune cells process antigens and help activate T cells against targets displaying the protein Gpnmb, which has been used before in experimental senolytic vaccination.
In naturally aged, normally fed mice vaccinated at 75 weeks, the CK5 formulation strengthened dendritic-cell and CD8 T-cell responses, cut senescence markers in fat tissue, and improved glucose regulation. Median lifespan rose about 12% versus untreated controls. Food intake and body weight did not shift enough to explain the gain.
How does this senolytic vaccine work?
The vaccine combines three parts: the Gpnmb antigen, a CpG DNA adjuvant that signals through TLR9, and a CK5 protein scaffold that forms nanoparticles roughly 90 nanometers across. The particles are meant to be taken up by dendritic cells, which then prime cytotoxic T cells.
Compared with a related K36 scaffold, CK5 delivered Gpnmb into the dendritic-cell cytosol more effectively and appeared to dial down Aurora kinases A and B. In cell tests, the CK5 vaccine reduced PI3K/AKT signaling and senescence-linked markers p16, p21, and p53 while keeping cells viable and boosting metabolic readouts.
In high-fat-diet mice vaccinated at 60 weeks, CK5 drove stronger CD8 responses, including interferon-γ and granzyme B expression. T cells from vaccinated mice killed more senescent Gpnmb-high cells in culture. Authors also reported roughly 50% lower senescence-associated β-galactosidase staining in visceral fat versus comparator vaccine groups, plus less liver fat buildup. Median lifespan reached 91 weeks versus 79–83 weeks in those comparator arms.
Why should lifespan results be read carefully?
The late-start 12% median gain is striking for an intervention begun so late in life. Still, each lifespan arm had only about 10 mice, and untreated controls lived shorter than typical for this strain. Short-lived controls are a known confounder in mouse longevity studies and can inflate apparent benefit.
AlphaFold3 predicted CK5–Aurora kinase contacts, but prediction alone does not prove the mechanism. Larger, better-controlled trials are needed before anyone can treat this as more than a promising proof of concept for immune-based senolytic strategies.